NewAmsterdam Pharma (NASDAQ:NAMSW – Get Free Report) is anticipated to issue its results before the market opens on Wednesday, November 11th. Analysts expect the company to post earnings of ($0.4949) per share and revenue of $7.54 million for the quarter.
NewAmsterdam Pharma Price Performance
NAMSW stock opened at $9.50 on Wednesday. NewAmsterdam Pharma has a 1 year low of $8.25 and a 1 year high of $30.45. The firm has a 50-day moving average of $12.05 and a 200 day moving average of $18.91.
NewAmsterdam Pharma Company Profile
NewAmsterdam Pharma Company N.V. is a clinical-stage biopharmaceutical company focused on developing therapies for dyslipidemia and other conditions associated with cardiovascular disease. Its lead product candidate is obicetrapib, an oral, low-dose cholesteryl ester transfer protein (CETP) inhibitor designed to reduce low-density lipoprotein cholesterol and improve patients’ lipid profiles.
The company is evaluating obicetrapib in late-stage clinical trials for patients whose cholesterol remains inadequately controlled despite existing treatment.
Further Reading
- Five stocks we like better than NewAmsterdam Pharma
- Tower Semiconductor’s Earnings Are Soaring—So Why Is Its Stock Down More Than 50%?
- Shopify’s Small Q3 Miss Triggered a Big Sell-Off: What’s Next?
- Can Oil’s Big Rally Deliver Reliable Income? 3 Energy Plays to Watch
- Marriott’s Earnings Beat Shows Why It’s More Than a Bet on Travel Demand
Receive News & Ratings for NewAmsterdam Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NewAmsterdam Pharma and related companies with MarketBeat.com's FREE daily email newsletter.
